Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25191707 | 1.00 | CRBN (0.44) | CRBNDDB1HCAR3CCNKCDK12 | |
| SCHEMBL30441229 | 1.00 | CRBN (0.44) | CRBNDDB1HCAR3CCNKCDK12 | |
| SCHEMBL25659085 | 0.91 | CRBN (0.46) | CRBNDDB1HCAR3CCNKCDK12 | |
| SCHEMBL30442072 | 0.91 | CRBN (0.46) | CRBNDDB1HCAR3CCNKCDK12 | |
| SCHEMBL25209326 | 0.91 | CRBN (0.46) | CRBNDDB1HCAR3CCNKCDK12 | |
| SCHEMBL25209327 | 0.91 | CRBN (0.46) | CRBNDDB1HCAR3CCNKCDK12 | |
| SCHEMBL30442212 | 0.91 | CRBN (0.46) | CRBNDDB1HCAR3CCNKCDK12 | |
| SCHEMBL25193804 | 0.89 | DDB1 (0.44) | CRBNDDB1 | |
| SCHEMBL25196574 | 0.89 | DDB1 (0.44) | CRBNDDB1 | |
| SCHEMBL30442052 | 0.89 | CRBN (0.43) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | CRBN 218/4885DDB1 675/4885HCAR3 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.